MRD in ALL: Optimization and Innovations
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,Hematology
Link
https://link.springer.com/content/pdf/10.1007/s11899-022-00664-6.pdf
Reference106 articles.
1. Bassan R. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood. 2009;113(18):4153–62. https://doi.org/10.1182/blood-2008-11-185132.
2. Brüggemann M. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood. 2006;107(3):1116–23. https://doi.org/10.1182/blood-2005-07-2708.
3. Mortuza FY. Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia. J Clin Oncol. 2002;20(4):1094–104. https://doi.org/10.1200/JCO.2002.20.4.1094.
4. Holowiecki J. Status of minimal residual disease after induction predicts outcome in both standard and high-risk Ph-negative adult acute lymphoblastic leukaemia. The Polish Adult Leukemia Group ALL 4-2002 MRD Study. Br J Haematol. 2008;142(2):227–37. https://doi.org/10.1111/j.1365-2141.2008.07185.x.
5. Patel B. Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993. Br J Haematol. 2010;148(1):80–9. https://doi.org/10.1111/j.1365-2141.2009.07941.x.
Cited by 9 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. The clinical applications of immunosequencing;Current Research in Translational Medicine;2024-09
2. Pediatric Leukemia Roadmaps Are a Guide for Positive Metastatic Bone Sarcoma Trials;Journal of Clinical Oncology;2024-09-01
3. Current and emerging sequencing-based tools for precision cancer medicine;Molecular Aspects of Medicine;2024-04
4. Circulating Tumor DNA Detection Technology and Its Application Value in Cancer Diagnosis and Treatment;PROG BIOCHEM BIOPHYS;2024
5. Relationship between subtype-specific minimal residual disease level and long-term prognosis in children with acute lymphoblastic leukemia;2024-01-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3